Pricing updated 2019-01-16. Prices are subject to change without notice.
(−)-CP 55,940 is a potent and non-selective cannabinoid (CB) receptor agonist with Ki values of 0.5 to 5 and 0.69 to 2.8 nM for CB1 and CB2 receptors, respectively.1 It is more potent than Δ9-THC (Item Nos. 12068 | ISO60157) in both behavioral tests and in receptor binding assays.2 In vivo, (−)-CP 55,940 administered intraperitoneally (0.3-3 mg/kg) or as an aerosol (0.72-72 mg/ml), suppresses locomotor activity, increases tail flick latency in a hot plate test for analgesia, and decreases body temperature in mice in a dose-dependent manner.3 Subchronic administration of (−)-CP 55,940 (0.03 mg/kg) also reduces body weight loss and running wheel activity in a rat model of anorexia nervosa.4
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands Curr. Med. Chem. 6(8), 635-664 (1999).
2. Wiley, J.L., Barrett, R.L., Lowe, J., et al. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats Neuropharmacology 34(6), 669-676 (1995).
Lefever, T.W., Marusich, J.A., Thomas, B.F., et al. Vaping synthetic cannabinoids: A novel preclinical model of E-
Scherma, M., Satta, V., Collu, R., et al. Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-